StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CERT$6.31+0.00%
Fair $6.31+0.0%

CERT

Certara, Inc.

Healthcare / Health Information ServicesNasdaqGS

$6.31

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $6.31Fund rank 34/100 · Data gapFallback financials|
SA 25/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 22% · confianza 25%

FCF escenarios

weak_data · normalized FCF $81.0M · quality 74.0/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 72/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

25/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 7Warnings: 1unknown: 7
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -0.2%, below the 5% threshold
Thesis & Journal · CERTLocal privado en este navegador · Certara, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$967M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-0.2%

↓

Gross Margin

N/A

•

Debt/Equity

0.27

↑
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2019–2025 · 6 años de histórico normalizado

Revenue CAGR

+12.3%

FCF CAGR

+17.5%

FCF margin

22.6%

FCF / Net income

-59.29x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $418.8M · net income $-1.6M · FCF $94.6M

2019-FY → 2025-FY

Gross margin

—— pts

Operating margin

5.0%-4.4% pts

Net margin

-0.4%+3.9% pts

FCF margin

22.6%+5.4% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
Income Statement
Revenue$418.8M$418.8M$385.1M$354.3M$335.6M$286.1M$243.5M$208.5M
Net Income$-1.6M$-1.6M$-12.1M$-55.4M$14.7M$-13.3M$-49.4M$-8.9M
EBITDA$96.2M$96.2M$66.3M$15.3M$34.3M$15.7M$-22.0M$22.2M
EPS-0.01-0.01-0.08-0.350.09-0.09-0.37-0.07
Operating Margin5.0%5.0%-0.4%-11.5%9.7%4.7%-10.0%9.4%
Net Margin-0.4%-0.4%-3.1%-15.6%4.4%-4.6%-20.3%-4.3%
Balance Sheet
Debt/Equity0.270.270.280.280.270.280.36—
Cash Flow
Free Cash Flow$94.6M$94.6M$78.8M$81.0M$91.1M$59.2M$43.9M$35.9M
Returns
ROE-0.2%-0.2%-1.1%-5.3%1.4%-1.3%-6.0%-1.8%
Growth & Yield
Revenue Growth8.7%8.7%8.7%5.6%17.3%17.5%16.8%—
EPS Growth87.5%87.5%77.1%-488.9%200.0%75.7%-428.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.